tbuckley/cabot-search huggingface dataset:
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.
Authors: Sara Elena Rebuzzi, Sebastiano Buti, Luca Galli, Giuseppe Procopio, Ugo De Giorgi, Cinzia Baldessari, Francesco Massari, Daniele Santini, Alessia Cavo, Giuseppe Luigi Banna, Mariella Soraru', Alessio Cortellini, Marco Messina, Valentino Martelli, Alessandra Damassi, Andrea Sbrana, Giulia Apollonio, Chiara Casadei, Alessio Signori, Giuseppe Fornarini
Journal: Journal of Clinical Oncology (2020)

752 Background: Biomarkers to select mRCC patients most likely to benefit to immune-checkpoint inhibitors are still needed. The ongoing retrospective multicentre Meet-URO 15 (I-BIO-REC) study evaluates the prognostic role of peripheral blood cells in mRCC patients treated with nivolumab. Methods:The primary endpoint of the study was median overall survival (mOS) according to bNLR. Complete blood count was collected at the first four cycles of nivolumab. NLR was defined as the ratio of neutrophil to lymphocyte (cutoff = 3) and ΔNLR the difference between NLR at 2nd cycle and bNLR (median used as cutoff = 0.3). Here we reported preliminary analyses on bNLR and DNLR. Results: From May 2016 to January 2019 189 patients started nivolumab as 2nd (62%), 3rd (25%) and &gt; 3rd (13%) line. Median age was 69 years, 67% were male and 87% had clear cell histology. Baseline IMDC group was favorable in 26%, intermediate in 63% and poor in 11%. Lymph-nodes, visceral and bone metastases were present in 55%, 92% and 37%. mOS and progression-free survival (PFS) were 30.5 months and 9.5 months. Overall response rate (ORR) and disease control rate (DCR) were 28% and 57%. bNLR was available in 162 patients: bNLR &lt; 3 (52%) correlated with statistically significant longer PFS [11.5 vs 5.6 months; HR 1.61 (1.09-2.39), p = 0.017] and OS [NR vs 22.4 months; HR 2.61 (1.53-4.46), p &lt; 0.001], with similar ORR (32% vs 32%) but higher DCR (66% vs 55%) compared to NLR ≥ 3. ΔNLR was available in 136 patients: ΔNLR &lt; 0.3 (50%) correlated with statistically significant longer PFS [17.1 vs 8.5 months; HR 1.57 (1.02-2.43) p = 0.04] and OS [medians not reached; HR 1.91 (1.04-3.51) p = 0.038], with similar ORR (39% vs 32%) but higher DCR (73% vs 56%) compared to ΔNLR ≥ 0.3. Univariate and multivariate analyses adjusted for IMDC group, line of therapy and metastatic sites, confirmed the statistically significant correlation between ΔNLR with PFS and OS and NLR with OS but not with PFS. Conclusions: Preliminary analyses of our study showed a prognostic role of bNLR and early ΔNLR in mRCC patients treated with nivolumab.
Fourteenth Biennial Report of the Board of State Commissioners of Public Charities for the Years 1895 and 1896.
Authors: Arthur R. Reynolds
Journal: JAMA (1897)

<h3>IMPROVEMENT OF ATTENDANTS IN HOSPITALS FOR THE INSANE.</h3> We believe that the State hospitals for the insane may well excite the pride of the citizens of Illinois. Their material equipment is admirable and in the whole their condition has undoubtedly never been as good as it is at this time. Such institutions, however, can not stand still. They must either retrograde or continually improve. The medical and nursing care should always command our greatest interest, and it is here as in educational institutions of the State, that there must be continuous progress if there is not to be retrogression. Early in 1896 the State Board of Charities sent out a list of inquiries to superintendents of hospitals for the insane in the United States regarding attendants or nurses. We present below a condensation of the replies received, fifty-eight in number. The inquiries were made because of the belief of the board,
Arrogance
Authors: Franz J. Ingelfinger
Journal: New England Journal of Medicine (1980)

IN this George W. Gay Lecture, specifically designated as "upon medical ethics," I shall focus on three issues. The first, an example of intergroup tensions, deals with the common accusation that bioscientists are arrogant, i.e., that they are presumptuous and overweening in their attitudes, decisions, and goals; that they exhibit, in the fashionable noun of the day, hubris. I shall argue that the bioscientist may be arrogant, but no more so than any other group and perhaps just a little bit less so.The second issue bears on the personal encounter between physician and patient: Is it marked by authoritarianism, . . .
A few words of thanks to a great many people
Authors: M. T. Southgate
Journal: JAMA (1977)

The relationship among all those who are responsible forThe Journal—from the editorial production staff to the advertisers, from the American Medical Association's Board of Trustees (under whose auspicesThe Journalis published) to the W. A. Krueger Company (who does the printing), and to persons in virtually every division of AMA's staff organization—is so complex, and their efforts so successfully blended, that once a contribution has gone into the common pot, only the final result, not the individual efforts, can be identified. Despite the impossibility of doing so adequately, however, there are some groups that we would single out for special mention; first, they are so seldom thought of in terms of what they contribute toThe Journal's success and second, the work they do, they do quietly, often anonymously, and always without financial remuneration. Paramount among these groups are our authors. True, in a world of
Allergic Rhinitis
Authors: Howard M. Druce
Journal: JAMA (1988)

<h3>SELECTED CASE</h3> A 28-YEAR-OLD medical resident presented to the allergy clinic with a two-year history of rhinorrhea, sneezing, and nasal obstruction. His symptoms were worse in the fall, and the nasal obstruction persisted intermittently throughout the winter. Four years previously he had moved to Washington, DC, from rural Oregon. On further questioning, the patient admitted to a decreased sense of smell and some wheezing on exertion. Over-the-counter therapy with various antihistamines and decongestants had produced initial relief, but this was not sustained. For editorial comment see p 267. The results of a physical examination were normal except for a finding of pale, boggy nasal turbinates. Topical nasal decongestion revealed the presence of bilateral nasal polyps. Skin tests were performed by the prick route to a battery of inhalant allergens. Significant positive results were obtained to ragweed, molds, house dust mites, and histamine control. The patient was prescribed a vigorous program
Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery
Authors: Christopher Rao, Omer Aziz, Sukhmeet Singh Panesar, Catherine Jones, Stephen Morris, Ara Darzi, Thanos Athanasiou
Journal: BMJ (2007)

Objective To compare the cost effectiveness of percutaneous transluminal coronary artery stenting with minimally invasive internal thoracic artery bypass for isolated lesions of the left anterior descending artery. Design Cost effectiveness analysis. Data sources Embase, Medline, Cochrane, Google Scholar, and Health Technology Assessment databases (1966-2005), and reference sources for utility values and economical variables. Methods Decision analytical modelling and Markov simulation were used to model medium and long term costs, quality of life, and cost effectiveness after either intervention using data from referenced sources. Probabilistic sensitivity and alternative analyses were used to investigate the effect of uncertainty about the value of model variables and model structure. Results Stenting was the dominant strategy in the first two years, being both more effective and less costly than bypass surgery. In the third year bypass surgery still remained more expensive but became marginally more effective. As the incremental cost effectiveness was £1 108 130.40 (€1 682 146.00; $2 179 194) per quality adjusted life year (QALY), the additional effectiveness could not be said to justify the additional cost at this stage. By five years, however, the incremental cost effectiveness ratio of £28 042.95 per QALY began to compare favourably with other interventions. At 10 years the additional effectiveness of 0.132 QALYs (range −0.166 to 0.430) probably justified the additional cost of £829.02 (range £205.56 to £1452.48), with an incremental cost effectiveness of £6274.02 per QALY. Sensitivity and alternative analysis showed the results were sensitive to the time horizon and stent type. Conclusions Minimally invasive left internal thoracic artery bypass may be a more cost effective medium and long term alternative to percutaneous transluminal coronary artery stenting.
Advertising and tobacco
Authors: E. Foote
Journal: JAMA (1981)

<h3>Statement Prepared for the Toronto Transit Commission</h3> It is not easy for me, a citizen of the United States, to make representations to a transit authority in another country, especially when my representations encourage a decision that would appear not to be in the authority's best financial interest. It is my understanding that the Toronto Board of Health has recommended that the Toronto Transit Commission refuse to accept future tobacco advertising. Both bodies are to be commended: your local health board for taking this preventive medical initiative and your commission for agreeing to review the matter. It is also my understanding that your local municipal councils, board of education, parent-teacher organizations, and various health and consumer groups all have supported the health board's recommendation. With a coalition like this, it is possible to make a desired health decision with widespread community backing. I cannot overstate the value of a positive
AMA EDUCATION AND RESEARCH FOUNDATION
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE UNIVERSAL CRAVING FOR ALCOHOL.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Publication bias and public health policy on environmental tobacco smoke
Authors: L. A. Bero
Journal: JAMA (1994)

<h3>Objective.</h3> —To examine the tobacco industry's claim that publication bias against negative studies invalidates the risk assessment of environmental tobacco smoke (ETS) conducted by the US Environmental Protection Agency and other reviews of the health effects of ETS. <h3>Design.</h3> —Determination of the number of published original research articles that tested the hypothesis that ETS exposure is associated with adverse health effects and that reported statistically significant ("positive") or nonsignificant ("negative") results; the number of articles that concluded that ETS is a health risk; and unpublished studies on the effects of ETS on health. <h3>Participants.</h3> —Articles identified by a computerized search of the medical literature supplemented with material obtained from the tobacco industry and hand searching. Articles were classified as peer-reviewed journal articles or articles from sponsored symposia. <h3>Main Outcome Measure.</h3> —The statistical significance of results reported in the article and whether or not the article concluded that ETS exposure is a health risk. <h3>Results.</h3> —More symposium articles than journal articles were reviews (46% vs 6%;<i>P</i>=.0001). More original journal articles than original symposium articles reported the use of statistical tests (96% vs 54%;<i>P</i>=.0001). Of articles with statistical analyses, similar proportions of journal articles and symposium articles reported statistically significant results (57% vs 47%;<i>P</i>=.329). The conclusions of 80% of the original journal articles were positive, compared with 51% of the original symposium articles (<i>P</i>=.006). <h3>Conclusions.</h3> —There is no publication bias against statistically nonsignificant results on ETS in the peer-reviewed literature. The high proportion of articles in symposia that reach the conclusion that ETS is not harmful primarily results from the inclusion of review articles. (<i>JAMA</i>. 1994;272:133-136)
Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).
Authors: Sandra P. D'Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, Douglas Adkins, Maria T. Grosse Perdekamp, Mercedes M. Condy, Eliza Woodward Hartley, Cristina R. Antonescu, Gary K. Schwartz, William D. Tap
Journal: Journal of Clinical Oncology (2014)

10568 Background: AS is a rare, aggressive, malignant endothelial cell tumor constituting 1-2% of all soft tissue sarcomas with 35% 5-yr survival. Cytotoxic agents have demonstrated ~15% response rates (RR). Gene-array data has revealed up-regulation of endothelial associated genes, including active members of the angiopoietin system [eg, Tie2 and Angiopoietin 2 (Ang2)]. Trebananib (AMG386) is a novel agent targeting Ang1 and Ang2. Methods: Metastatic/unresectable AS, adequate performance status, organ function, and measurable disease (RECIST v1.1) were required. Trebananib 30mg/kg d1, 8, 15, and 22 was repeated q28 days until progressive disease (PD) or unacceptable toxicity. The primary endpoint is confirmed RR (partial or complete by RECIST v1.1); 1 response in 12 pts expanded enrollment to 25. Secondary endpoints include: toxicity, progression-free survival (PFS), and overall survival (OS). Correlatives include: 1) baseline expression of Ang2/Tie2 by immunohistochemistry (IHC), 2) serum levels of Ang1, 3) pre- and post-treatment phospho-receptor tyrosine kinase and 4) MYC/FLT4 amplification status. Results: 16 pts were enrolled from 5 participating sites [median age 68 yrs (24-91), 38% male, median number of prior therapies 2.5 (1-7)]. No confirmed responses were observed in 14 evaluable pts; one pt had an 18% decrease. 4/16 had SD, 12/16 have PD; 8/16 have died with a median follow-up of 2.9 mos (0.9-12.7). Estimated median and 12-week PFS rate are 7 weeks (95% 6-8) and 25% (95% CI 11-58%), respectively. Median OS is 28 weeks (95% CI 17-48). Common grade 3-4 adverse events include (pts): thrombosis (2), syncope (1), anemia (1). Two pts died of reasons unrelated to treatment (cardiac, respiratory failure). Conclusions: Trebananib was well-tolerated in this phase II study of AS, with no partial/complete responses. Prolonged PFS was observed in 4 pts, lasting 3.5-5.5 mos. Forthcoming results of the associations of correlatives (eg, Ang/Tie2 IHC expression and serum Ang levels) with outcome may help identify patients most likely to benefit. Clinical trial information: NCT01623869.
Safety-Belt and Helmet Use Among High School Students—United States, 1990
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reticuloendothelial function
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hickory Dickory Dock / Who's Inherited Mousie's Clock?
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neglect—Not Football—Blamed For Injuries in Sports Program
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Weight Loss vs Exercise to Reduce Coronary Artery Disease Risk Factors-Reply
Authors: Leslie I. Katzel
Journal: JAMA (1996)

<h3>In Reply.</h3> —Dr Greenberg raises an important public health issue concerning recommendations for subjects who are moderately obese. The available data suggest that even moderately obese individuals would improve their CAD risk factor profiles if they lost weight.<sup>1</sup>Given that age-associated declines in leisure time physical activity and lean muscle mass adversely impact energy expenditure, in practice it may be difficult for moderately obese, older individuals to lose significant amounts of weight unless they partake in some form of exercise training. Adoption of public health guidelines advocating weight loss to a BMI of less than 22.5 kg/m<sup>2</sup>must be tempered by data that demonstrate that the BMI associated with the lowest total mortality may be higher at 26 to 27 kg/m<sup>2</sup>in the elderly than in middle-aged populations.<sup>2</sup>We agree that large-scale clinical trials will be required to define the role of weight loss and exercise